On Friday, Dexcom Inc (NASDAQ: DXCM) opened lower -1.72% from the last session, before settling in for the closing price of $67.30. Price fluctuations for DXCM have ranged from $57.52 to $141.25 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 22.46%. Company’s average yearly earnings per share was noted 23.37% at the time writing. With a float of $386.62 million, this company’s outstanding shares have now reached $390.70 million.
Let’s determine the extent of company efficiency that accounts for 10300 employees. In terms of profitability, gross margin is 60.41%, operating margin of 14.88%, and the pretax margin is 17.58%.
Dexcom Inc (DXCM) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Dexcom Inc is 1.41%, while institutional ownership is 92.53%. The most recent insider transaction that took place on Mar 17 ’25, was worth 24,756. In this transaction Director of this company sold 352 shares at a rate of $70.33, taking the stock ownership to the 22,997 shares. Before that another transaction happened on Mar 17 ’25, when Company’s Director proposed sale 352 for $70.33, making the entire transaction worth $24,756.
Dexcom Inc (DXCM) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.48 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.37% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.83% during the next five years compared to 39.06% growth over the previous five years of trading.
Dexcom Inc (NASDAQ: DXCM) Trading Performance Indicators
Check out the current performance indicators for Dexcom Inc (DXCM). In the past quarter, the stock posted a quick ratio of 1.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.43. Likewise, its price to free cash flow for the trailing twelve months is 41.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.42, a number that is poised to hit 0.33 in the next quarter and is forecasted to reach 2.48 in one year’s time.
Technical Analysis of Dexcom Inc (DXCM)
Looking closely at Dexcom Inc (NASDAQ: DXCM), its last 5-days average volume was 6.87 million, which is a jump from its year-to-date volume of 4.18 million. As of the previous 9 days, the stock’s Stochastic %D was 63.50%. Additionally, its Average True Range was 3.75.
During the past 100 days, Dexcom Inc’s (DXCM) raw stochastic average was set at 24.13%, which indicates a significant decrease from 46.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.87% in the past 14 days, which was higher than the 42.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $77.82, while its 200-day Moving Average is $79.06. However, in the short run, Dexcom Inc’s stock first resistance to watch stands at $67.54. Second resistance stands at $68.93. The third major resistance level sits at $70.21. If the price goes on to break the first support level at $64.87, it is likely to go to the next support level at $63.59. Now, if the price goes above the second support level, the third support stands at $62.20.
Dexcom Inc (NASDAQ: DXCM) Key Stats
There are currently 392,107K shares outstanding in the company with a market cap of 25.93 billion. Presently, the company’s annual sales total 4,033 M according to its annual income of 576,200 K. Last quarter, the company’s sales amounted to 1,114 M and its income totaled 151,700 K.
